Research programme: autoimmune disorder therapeutics - Agenus
Alternative Names: AU-801Latest Information Update: 07 Mar 2011
Price :
$50 *
At a glance
- Originator Antigenics
- Developer Agenus
- Class
- Mechanism of Action Immunosuppressants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Diabetes mellitus; Multiple sclerosis; Rheumatoid arthritis
Most Recent Events
- 07 Mar 2011 No development reported - Preclinical for Diabetes mellitus in USA (unspecified route)
- 07 Mar 2011 No development reported - Preclinical for Multiple sclerosis in USA (unspecified route)
- 07 Mar 2011 No development reported - Preclinical for Rheumatoid arthritis in USA (unspecified route)